Rifaximin Significantly Improves Quality of Life Versus Placebo in Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Authors :: Nicholas J. Talley
Jing Yu
Enoch Bortey
Anthony Lembo
William Y. Chey
Source :: American Journal of Gastroenterology. 103:S461-S462
Publication Year :: 2008
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2008.

Subjects :: medicine.medical_specialty
Hepatology
business.industry
Gastroenterology
medicine.disease
Placebo
Rifaximin
chemistry.chemical_compound
Diarrhea
chemistry
Quality of life
Internal medicine
medicine
In patient
medicine.symptom
business
Irritable bowel syndrome

Full Text Access

Tools